Pharmacists must be aware of potentially serious adverse reactions in patients receiving angiotensin- converting enzyme therapy, particularly with the concurrent use of dipeptidly peptidase IV inhibitors.
Saleem Ahmad, PhD, RPh
Advertisement
Articles by Saleem Ahmad, PhD, RPh
Advertisement
Latest Updated Articles
- Treatment of Diabetes and Angioedema Risk
Published: October 10th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
FDA Approves First Drug for Pediatrics With Irritable Bowel Syndrome With Constipation
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
5
